Invited speakers

Jenn Abelin, Ph.D Senior Group Leader, Proteomics Platform, Broad Institute Affiliated Researcher of Dana-Farber Cancer Institute’s Translational Immunogenomics Lab (TIGL)  

Jenn Abelin is a Senior Group Leader in the Proteomics Platform at the Broad Institute of MIT and Harvard. Dr. Abelin, the HLA team, and their collaborators work closely together to develop and apply mass spectrometry-based immunopeptidomics to identify peptides displayed to T cells by HLA-I and HLA-II cell surface molecules, which play a major role in adaptive immune responses. Immunopeptidomics enables a deeper understanding of antigen processing and presentation and allows the direct identification of disease specific HLA-I and HLA-II bound peptides, which are putative therapeutic targets.